267 related articles for article (PubMed ID: 12482941)
21. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.
Svensson K; Carlsson A; Huff RM; Kling-Petersen T; Waters N
Eur J Pharmacol; 1994 Oct; 263(3):235-43. PubMed ID: 7843260
[TBL] [Abstract][Full Text] [Related]
22. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
[TBL] [Abstract][Full Text] [Related]
23. The effect of repeated treatment with pramipexole on the central dopamine D3 system.
Maj J; Rogói Z; Margas W; Kata M; Dziedzicka-Wasylewska M
J Neural Transm (Vienna); 2000; 107(12):1369-79. PubMed ID: 11458990
[TBL] [Abstract][Full Text] [Related]
24. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
25. D-3 receptor agonists: combined action neurologic and neuropsychiatric agents.
Cummings JL
J Neurol Sci; 1999 Feb; 163(1):2-3. PubMed ID: 10223401
[No Abstract] [Full Text] [Related]
26. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
[TBL] [Abstract][Full Text] [Related]
27. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
[TBL] [Abstract][Full Text] [Related]
28. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.
Morissette M; Goulet M; Grondin R; Blanchet P; Bédard PJ; Di Paolo T; Lévesque D
Eur J Neurosci; 1998 Aug; 10(8):2565-73. PubMed ID: 9767387
[TBL] [Abstract][Full Text] [Related]
29. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
30. Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists.
Kolasiewicz W; Maj J
Pol J Pharmacol; 2001; 53(5):509-15. PubMed ID: 11990070
[TBL] [Abstract][Full Text] [Related]
31. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Presgraves SP; Borwege S; Millan MJ; Joyce JN
Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
[TBL] [Abstract][Full Text] [Related]
32. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
Darmani NA; Crim JL
Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
[TBL] [Abstract][Full Text] [Related]
33. Dopamine D(1) agonist activates temporal lobe structures in primates.
Black KJ; Hershey T; Gado MH; Perlmutter JS
J Neurophysiol; 2000 Jul; 84(1):549-57. PubMed ID: 10899226
[TBL] [Abstract][Full Text] [Related]
34. Baseline Perfusion Alterations Due to Acute Application of Quetiapine and Pramipexole in Healthy Adults.
Michels L; Scherpiet S; Stämpfli P; Herwig U; Brühl AB
Int J Neuropsychopharmacol; 2016 Nov; 19(11):. PubMed ID: 27466220
[TBL] [Abstract][Full Text] [Related]
35. Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
Lieberknecht V; Junqueira SC; Cunha MP; Barbosa TA; de Souza LF; Coelho IS; Santos AR; Rodrigues AL; Dafré AL; Dutra RC
Mol Neurobiol; 2017 Mar; 54(2):1033-1045. PubMed ID: 26801190
[TBL] [Abstract][Full Text] [Related]
36. Association between striatal dopamine D2/D3 receptors and brain activation during visual attention: effects of sleep deprivation.
Tomasi D; Wang GJ; Volkow ND
Transl Psychiatry; 2016 May; 6(5):e828. PubMed ID: 27244237
[TBL] [Abstract][Full Text] [Related]
37. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
Ramirez AD; Wong SK; Menniti FS
Eur J Pharmacol; 2003 Aug; 475(1-3):29-35. PubMed ID: 12954356
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects.
Le Foll B; Sokoloff P; Stark H; Goldberg SR
Neuropsychopharmacology; 2005 Apr; 30(4):720-30. PubMed ID: 15562293
[TBL] [Abstract][Full Text] [Related]
39. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44.
Weber M; Chang WL; Durbin JP; Park PE; Luedtke RR; Mach RH; Swerdlow NR
Pharmacol Biochem Behav; 2009 Aug; 93(2):141-7. PubMed ID: 19426754
[TBL] [Abstract][Full Text] [Related]
40. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
